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Abstract
Monitoring increased plasma unbound free
fatty acid (FFAu) concentrations has been pro-
posed as a biomarker for myocardial ischemia.
In the current study, 30 acute coronary syn-
drome (ACS) patients presenting in the emer-
gency department, with chest pain within 12 h
of onset, were clinically evaluated along with
serial cardiac troponin I (cTnI) and FFAu
measurements.
Increased FFAu were found in 28 of 30
(93%) of ACS patients, ranging from 2.0 to
430 nM. For the nine ACS patients with
myocardial infarction (MI), FFAu levels were
increased at presentation for all (100%). In con-
trast, cTnI was increased in only 9 of 30 (30%)
patients, mean 0.7 µg/L, and in only 2 of 9
(22%) MI patients, mean 1.3 µg/L. During the
24 h following admission, cTnI increased in all
9 MI patients. FFAu concentrations increased in
every sample in which cTnI increased.
Our findings suggest that FFAu is increased
in ischemia regardless of the presence or
absence of myocardial necrosis, as reflected by
increased or normal cTnI, respectively.
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Introduction
Myocardial ischemia (MI) generates a vari-
ety of cellular events within minutes of the
interruption of blood flow that stimulate the
release of plasma free fatty acids (FFA).
Increases of total plasma FFA concentrations
are found in patients with acute MI shortly
after the event (1,2). A method has been devel-
oped to measure the unbound (FFAu) fraction
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of total plasma FFA (2–4). As demonstrated
earlier, levels of FFAu increase within 30 min
of balloon inflation in patients undergoing
percutaneous transluminal coronary angio-
plasty (PTCA), even in the absence of necrosis
(5). To evaluate the potential diagnostic utility
of FFAu, plasma FFAu and cTnI were mea-
sured in patients presenting with chest pain
presumed to be of myocardial origin. 
Methods
The study population comprised 30 patients
between the ages of 35 and 79 yr, 18 men and
12 women, presenting with chest pain to Hen-
nepin County Medical Center’s emergency
department between April 1998 and June 1999.
All patients presented with sustained chest
pain of at least 10 min within the preceding
12 h and had a clinical diagnosis from the
attending physician of ischemia. However
no standard confirmation test for detecting
ischmia was available; neither were stress tests
or cardiac catheterizations. Eight of these
patients had additional diagnoses that have
been associated with myocardial injury (MI)
(i.e., trauma 4, cocaine-2, third-degree burns-1,
sepsis-1). All patients were evaluated with
serial cTnI monitoring at presentation (0 h)
and additional samplings during hospitaliza-
tion. Nine patients had a diagnosis of an MI
established by their cardiologists using ECG
and cTnI values that were available to the clin-
icians at the time. Patients were enrolled prior
to release of the ESC/ACC consensus guide-
lines for the redefinition of MI in September
2000 (6), and thus the criteria used by the local
physicians for MI diagnosis followed World
Health Organization (WHO) guidelines (7).
The remaining 21 patients had chest discom-
fort consistent with angina pectoris, and 17 of
these 21 had abnormal electrocardiograms
(ECG)s consistent with ischemia.
Plasma (heparin) was obtained at pre-
sentation and at least two more times during
hospitalization. All samples were frozen and
maintained at –70°C prior to analysis. Samples
were blinded for measurements of FFAu, cTnI,
and patient diagnoses. cTnI for the purposes
of this evaluation was measured using the
Ortho Clinical Diagnostics (OCD) Vitros cTnI
assay (8), with an upper reference limit of
0.12 µg/L, defined at the 10% imprecision con-
centration (9). FFAu was determined using the
ADIFAB2 fluorescent molecular probe, as
described previously for the earlier ADIFAB
probe (3,4). The present measurements with
ADIFAB2 were done at 22°C, were not affected
by hemoglobin, and showed improved low
end sensitivity. Duplicate measurements were
done for each sample, with a coefficient of
variation of 7%. The FFAu reference limit
(determined from 48 healthy subjects) was
< 2.7 nM (mean 1.5 [SD 0.6] nM; range 0.6–4.5
nM). The institutional review board approved
the protocol.
Results
Levels of FFAu were increased at presenta-
tion in 28 of 30 (93%) patients with chest pain;
range of all values were from 2.0 to 430 nM,
mean 31 (SD 61) nM (Fig. 1). All nine patients
with a diagnosis of MI had increased FFAu at
presentation. Of the two non-MI patients with-
out an increased FFAu at presentation, one
revealed increased levels within 6 h (change
from 2.5 to 4.3 nM); whereas the other never
increased above 2.6 nM over 3 h. FFAu
remained increased for 6 to 64 h in the 29
patients with increased concentrations. 
Using reference limit criteria for levels of
cTnI measured with the OCD assay, it was
determined that at presentation cTnI was
increased in 7 of 21 patients (33%) classified as
not having a MI (mean 0.7 [SD 1.8] µg/L) and
in only two of nine MI patients (22%) (mean
1.3 [SD 3.0] µg/L). cTnI became increased in
all nine MI patients and in an additional two
non-MI patients (9 of 21 overall) over time.
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FFAu were increased in every sample in which
TnI was increased. 
Discussion
These data suggest that plasma FFAu are
increased in patients presenting with ischemic,
chest pain presumed to be of cardiac origin.
Previous studies of chest pain patients demon-
strated that total plasma FFAu are increased
in MI patients (1,2). Previous studies have
also shown that FFAu concentrations were
increased significantly 30 min after PTCA bal-
loon inflation and preliminary results indicate
increased FFAu in patients with transmural MI
and acute coronary syndromes (5,10,11). 
The present study suggests that FFAu is
increased by ischemia regardless of the pres-
ence or absence of necrosis, as reflected by the
absence or presence of increased cTnI. FFAu
was increased in every instance that cTnI was
increased and there was a trend towards posi-
tive correlation between peak FFAu and cTnI
concentration. Additionally, in MI patients,
FFAu was increased in 100% patients at pre-
sentation, whereas only 22% of these patients
revealed increases in cTnI at presentation,
indicative of the earlier appearance of this ana-
lyte in the circulation before traditional mark-
ers of myocyte necrosis. Some of these patients
were ultimately diagnosed with additional
diagnoses that can cause myocardial ischemia
and injury (such as sepsis, cocaine abuse, and
cardiac contusion) independent of plaque rup-
ture. This suggests that levels of FFAu may
increase early in the presence of acute myocar-
dial injury and ischemia independent of plaque
rupture. Further studies are warranted to eval-
uate the potential clinical utility of FFAu in the
evaluation of patients who present to the emer-
gency department with chest pain. We recog-
nize the limitations of the lack of an objective
standard for detecting ischemia and sparse clin-
ical information available. However, the poten-
tially important finding of this this study is the
early detection of ischemia with FFAu.
In summary, our data suggests that in
patients presenting with ischemic, chest pain
plasma FFAu monitoring may provide an early
indication of cardiac ischemia in the absence or
presence of necrosis based on cardiac troponin I
monitoring. We demonstrated that nine of nine
MI patients had an increased FFAu vs two of
nine for cTnI. In chest pain patients, 93% had
an increased FFAu compared to increases in
30% for cTnI.
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Fig. 1. FFAu and cTnI concentrations in normal sub-
jects and chest pain patients. FFAu are represented as
diamonds and cTnI as circles. Normals are shown for
FFAu only. Box plots indicate median and 25th and
75th percentiles of FFAu for normals; FFAu and cTnI
at presentation; maximum FFAu and cTnI over hospi-
talization. ULN = upper limit of normal.
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
44 __________________________________________________________________ Apple, Kleinfeld, and Adams
4. Richieri GV, Ogata RT, Kleinfeld AM. The
measurement of free fatty acid concentration
with the fluorescent probe ADIFAB: a practical
guide for the use of the ADIFAB probe. Mol
Cell Biochem 1999;192:87–94.
5. Kleinfeld AM, Prothro D, Brown D, Davis RC,
Richierie GV, DeMaria A. Increases in serum
unbound free fatty acid concentrations fol-
lowing coronary angioplasty. Am J Cardiol
1996;78:1350–1354.
6. Myocardial infarction redefined—a consensus
document of the Joint European Society of
Cardiology/American College of Cardiology
Committee for the redefinition of myocardial
infarction. Eur Heart J 2000;21:1502–1513.
7. Falahati A, Sharky SW, Christenson D, McCoy
M, Miller E, Murakami MM, Apple FS. Imple-
mentation of cardiac troponin I for detection
of acute myocardial injury in an urban medi-
cal center. Am Heart J 1999;137:332–337; letter
correction 1999;138:798–800.
8. Apple FS, Koplen B, Murakami MM. Prelimi-
nary evaluation of the Ortho ECi cardiac tro-
ponin I immunodiagnostic assay. Clin Chem
2000;46:572–574.
9. Apple FS, Wu AHB, Jaffe AS. European 
Society of Cardiology and American College
of Cardiology guidelines for definition of
myocardial infarction—how to use existing
assay clinically and for clinical trials. Am
Heart J 2002;981–986.
10. Kleinfeld AM, Kleinfeld KJ, Adams JE. Serum
levels of unbound free fatty acids reveal high
sensitivity for early detection of acute myocar-
dial infarction in patient samples from the
TIMI II trial. JACC 2002;39:312A.
11. Adams JE, Kleinfeld A, Roe M, Yang H, Chris-
tenson RH, Ohman EM, Gibler WB, Measure-
ment of levels of unbound free fatty acid
allows the early identification of patients with
acute coronary syndromes. Circulation 2002;
Supplement:II–532.
